Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risvutatug Rezetecan in Advanced or Metastatic Sarcomas
NCT07602777Phase 2Recruiting
- Sponsor
- GSK
- Start
- Jun 2026
- Primary completion
- Nov 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of risvutatug rezetecan in osteosarcoma (OS) and soft tissue sarcoma (STS) (3 cohorts), sponsored by GSK. Primary endpoints: Progression-Free Survival Rate at Week 18 and Confirmed Objective Response Rate at 98 weeks. Started Jun 2026; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
osteosarcoma (OS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07602777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07602777.